Viral hepatitis and inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 6, 2010, Pages 925-932

  Hou, Jason K ^a   Velayos, Fernando ^b   Terrault, Norah ^b   Mahadevan, Uma ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Hepatitis A; Hepatitis B; Hepatitis C; Inflammatory bowel disease; Ulcerative colitis; Vaccination; Viral hepatitis

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; LAMIVUDINE; PEGINTERFERON; PLACEBO; PREDNISONE; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR INHIBITOR;

ENTERITIS; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCREENING; VACCINATION; VIRUS REPLICATION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERFERONS; MALE; PRACTICE GUIDELINES AS TOPIC; PREDNISONE; PREGNANCY; RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA; VIRAL HEPATITIS VACCINES;

EID: 77952697076     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21284     Document Type: Review

References (55)

1. World Health Organization. Immunization, vaccines and biologicals, hepatitis B. Available at: http://www.who.int/immunization/topics/ hepatitis-b/en/index.html Accessed November 11, 2008.
2. Centers for Disease Control http://www.cdc.gov/hepatitis/statistics.htm
3. [No authors listed.] NIH Consensus Statement on Management of Hepatitis C. NIH Consens State Sci Statements. 2002;19:1-46.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
5. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy- induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11:965-991, x.
6. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299-307.
7. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182-188.
8. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. (Pubitemid 36734719)
9. Biancone L, Pavia M, Del Vecchio Blanco G, et al., Italian Group for the Study of the Colon and Rectum (GISC). Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001;7:287-294.
10. Longo F, Hebuterne X, Tran A, et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol. 2000;24:77-81. (Pubitemid 30117236)
11. Loras C, Saro C, Gonzalez-Huix F, et al., GETECCu (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol. 2009;104: 57-63.
12. Tolentino YF, Fogaca HS, Zaltman C, et al. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. World J Gastroenterol. 2008;14:3201-3206.
13. Chevaux JB, Bigard MA, Bensenane M, et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009 [Epub ahead of print].
14. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974-976.
15. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007;13: 1453-1454. (Pubitemid 350206866)
16. Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis. 2007;13:1450-1451. (Pubitemid 350206863)
17. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365. (Pubitemid 39120128)
18. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13: 508-509. (Pubitemid 46668261)
19. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008;43:397-401. (Pubitemid 351958904)
20. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci. 2005;50:163-166. (Pubitemid 40379157)
21. Yoshioka K, Kakumu S, Arao M, et al. Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease. J Clin Pathol. 1990;43:298-302. (Pubitemid 20111780)
22. Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet. 2003;12:2541-2546. (Pubitemid 37220418)
23. Zeitz J, Mullhaupt B, Fruehauf H, et al. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology. 2009;50:653-654.
24. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis. 2003;36:1602-1605. Erratum: Clin Infect Dis 2003;37:157.
25. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009;7:1130-1137.
26. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59-68.
27. Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15: 89-102.
28. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233-240. (Pubitemid 43303991)
29. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742-1749.
30. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47:844-853. (Pubitemid 351449676)
31. Gupta A, Macrae FA, Gibson PR. Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologists. Intern Med J. 2009 [Epub ahead of print].
32. Vida Pérez L, Gómez Camacho F, García Sánchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132:331-335.
33. Ghany MG, Strader DB, Thomas DL, et al., American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
34. Sümer N, Palabiyikocombining x abovelu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol. 1995;7:597-602.
35. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther. 2002;16:1233-1239.
36. Musch E, Andus T, Kruis W, et al. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, doubleblind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2005;3: 581-586. (Pubitemid 40824751)
37. Villa F, Rumi MG, Signorelli C, et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol. 2005;17:1243-1245. (Pubitemid 41527444)
38. Morimoto K, Yamagami H, Hosomi S, et al. Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery. Am J Gastroenterol. 2009;104:1609-1610.
39. Watanabe T, Inoue M, Harada K, et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut. 2006;55:1682-1683. (Pubitemid 44629245)
40. Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut. 2005;54:438-439. (Pubitemid 40299105)
41. Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis. 2007;13:1189-1190. (Pubitemid 47402611)
42. Mavrogiannis C, Papanikolaou IS, Elefsiniotis IS, et al. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. J Hepatol. 2001;34:964-965. (Pubitemid 32595203)
43. Khalil A, Lucidarme D, Desurmont P, et al. Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C. Gastroenterol Clin Biol. 2005;29:193-196. (Pubitemid 40385081)
44. Tilg H, Vogelsang H, Ludwiczek O, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut. 2003;52:1728-1733. (Pubitemid 37510393)
45. Seow CH, Benchimol EI, Griffiths AM, et al. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2008;:CD006790.
46. Bargiggia S, Thorburn D, Anderloni A, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005;22:209-215. (Pubitemid 41153063)
47. Scherzer TM, Staufer K, Novacek G, et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008;28:742-748.
48. Lin A, Thadareddy A, Goldstein MJ, et al. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol. 2008;80:1720-1722.
49. Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver. 1996;16:390-399. (Pubitemid 27042775)
50. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315-322.
51. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13:191-192. (Pubitemid 32158214)
52. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078-1078
53. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, et al. Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients. Hepatology. 2008;48:348-349.
54. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11:386-395. (Pubitemid 40533206)
55. Zekry A, Gleeson M, Guney S, et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004;10:52-57. (Pubitemid 38885893)